En Es
Categorías

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initia ...
Productos Covid-19NoticiasResumen
Close

Covid-19 QIAGEN

Laboratorio clínico

Viral RNA UM Kit
QIAprep& Viral RNA UM Kit

The QIAprep& Viral RNA UM Kit combines a liquid-based sample preparation step completed in only two minutes with real-time RT-PCR detection in a streamlined workflow. Users can automate this method with standard lab equipment for any throughput, assay and reaction need from single to multiplex testing. The kit is compatible with dual-labeled probes, e.g., TaqMan probes in multiplex one-step RT-PCR detection of one or more targets (altogether, up to 4 assays including the internal controls).
Mas detalles

SARS-CoV-2 Primer Panel
QIAseq SARS-CoV-2 Primer Panel

The QIAseq SARS-CoV-2 Primer Panel combines both reverse transcription and whole genome enrichment of the viral RNA for targeting SARS-CoV-2 to generate amplicons for downstream library creation. When paired with a QIAseq FX DNA Library UDI Kit, sequencing-ready libraries compatible with Illumina platforms can be constructed. QIAseq SARS-CoV-2 primer pools utilize designs from the ARTIC V3 primers which have also gone through an in silico check to reduce chances for dimerization during sample enrichment.
Mas detalles

SARS-CoV-2 Antigen Testing Device
QIAreach eHub

The QIAreach eHub portable SARS-CoV-2 antigen testing device, in combination with QIAreach assay eSticks, provides a simplified workflow for multiple in vitro diagnostic tests, using state-of-the-art nanoparticle fluorescence detection technology. QIAreach assay eSticks are single-use tests that include a lateral flow strip and optoelectronics that perform test measurements and interpret results. The QIAreach eHub provides power to the QIAreach test eStick to run the test when the test eStick is connected to any one of the eHub eStick ports. The QIAreach eHub visually communicates test progress and results to the user via a display screen specific to each eHub port.
Mas detalles

SARS-CoV-2 RUO Solution
QuantiFERON SARS-CoV-2 RUO

The QuantiFERON SARS-CoV-2 RUO solution is an original combination of blood collection tubes containing innovative specific peptides formulated to stimulate lymphocytes in heparinized whole blood involved in cell-mediated immunity. Plasma from the stimulated samples can then be used for detection of IFN-γ using a simple ELISA. The QuantiFERON SARS-CoV-2 RUO solution is composed of several components that can be ordered separately or combined to provide better research insights on patients’ immune status.
Mas detalles

Flu A/SARS-CoV-2 Test
NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test

The NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test is a multiplex polymerase chain reaction (PCR) test that detects and differentiates influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minutes. The respiratory test takes advantage of the NeuMoDx 96 and NeuMoDx 288 molecular systems’ automated three-step workflow and has obtained CE-IVD approval for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit, which includes a collection vial, stabilization tube and pipette.
Mas detalles

SARS-CoV-2 Assay
NeuMoDx SARS-CoV-2 Assay

The NeuMoDx SARS-CoV-2 Assay is a real-time RT-PCR diagnostic test intended for the qualitative detection of SARS-CoV-2 coronavirus RNA in nasal, nasopharyngeal and oropharyngeal swabs in transport medium, and bronchoalveolar lavage (BAL) specimens from individuals suspected of COVID-19 by their healthcare provider. This test is performed on the NeuMoDx 288 and NeuMoDx 96 Molecular Systems and is also for use with saliva specimens that are collected within a healthcare setting by individuals using the NeuMoDx Saliva Collection Kit when determined to be appropriate by a healthcare provider.
Mas detalles

Molecular System
NeuMoDx 96

The NeuMoDx 96 Molecular System is designed for the automated extraction and isolation of nucleic acids, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR. Consisting of the instrument with touchscreen computer, accessories, and reagents and consumables, the system is intended for in vitro diagnostic (IVD) use in performing NeuMoDx-validated nucleic acid testing in clinical laboratories.
Mas detalles

Molecular System
NeuMoDx 288

The NeuMoDx 288 Molecular System is designed for the automated extraction and isolation of nucleic acids, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR. Consisting of the instrument with touchscreen computer, accessories, and reagents and consumables, the instrument is intended for in vitro diagnostic (IVD) use in performing NeuMoDx-validated nucleic acid testing in clinical laboratories.
Mas detalles

SARS-CoV-2 Antigen Test
QIAreach SARS-CoV-2 Antigen Test

The QIAreach SARS-CoV-2 Antigen Test is a scalable, digital assay for the in vitro detection of the SARS-CoV-2 nucleocapsid protein antigen that allows testing up to eight patients simultaneously for SARS-CoV-2 infection with the first positive results in just two minutes. As part of the complete QIAreach solution for SARS-CoV-2 testing, the test will run simultaneously with the QIAreach Anti-SARS-CoV-2 Total Test on a single QIAreach eHub.
Mas detalles

SARS-CoV-2 Antibody Test
QIAreach Anti-SARS-CoV-2 Total Test

The QIAreach Anti-SARS-CoV-2 Total Test is a rapid, digital lateral flow serological test, using nanoparticle fluorescence, intended for qualitative detection of total antibodies to SARS-CoV-2 in human serum and plasma (heparin, EDTA). It is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Mas detalles

PANEL RESPIRATORIO SARS-COV-2
QIAstat-Dx Respiratory SARS-CoV-2 Panel

El panel QIAstat-Dx Respiratory SARS-CoV-2 es un cartucho sindrómico multiplex que detecta y diferencia 21 objetivos respiratorios, incluido el SARS-CoV-2 de hisopos nasofaríngeos (NPS) eluídos en medios de transporte universal (MTU).
Mas detalles
Close

Noticias of QIAGEN

Qiagen hace una sociedad con Sysmex para el desarrollo y la comercialización de diagnósticos acompañantes para el cáncer

24 Aug 2021
Qiagen hace una sociedad con Sysmex para el desarrollo y la comercialización de diagnósticos acompañantes para el cáncer
QIAGEN NV (Venlo, Países Bajos) y Sysmex Corporation (Kobe, Japón) firmaron una alianza estratégica global para el desarrollo y comercialización de diagnósticos complementarios del cáncer, que aprovechará tanto el liderazgo de QIAGEN en este campo como la tecnología Plasma-Safe-SeqS de Sysmex para secuenciación de próxima generación (NGS).
Más info

Qiagen Partners with Sysmex for Development and Commercialization of Cancer Companion Diagnostics

02 Jul 2021
Qiagen Partners with Sysmex for Development and Commercialization of Cancer Companion Diagnostics
QIAGEN N.V. (Venlo, Netherlands) and Sysmex Corporation (Kobe, Japan) have entered into a global strategic alliance for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing (NGS).
Más info

QIAGEN to Focus on Molecular Testing amidst Coronavirus Pandemic after Voluntary Public Takeover Offer by Thermo Fisher Falls Short

14 Aug 2020
QIAGEN to Focus on Molecular Testing amidst Coronavirus Pandemic after Voluntary Public Takeover Offer by Thermo Fisher Falls Short
QIAGEN N.V. (Venlo, Netherlands) plans to continue executing its growth strategy aimed at creating significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific Inc. (Waltham, MA, USA) failed to achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders.
Más info

QIAGEN Enters into Agreement to Acquire STAT-Dx

13 Feb 2018
QIAGEN Enters into Agreement to Acquire STAT-Dx
QIAGEN N.V. has entered into an agreement to acquire STAT-Dx, a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.
Más info

Qiagen Acquires Bioinformatics Firm OmicSoft

12 Jan 2017
Qiagen Acquires Bioinformatics Firm OmicSoft
QIAGEN N.V., a provider of sample and assay technologies, has acquired OmicSoft Corporation, which focuses on biomarker data management, visualization, and analysis.
Más info
Close

Sobre QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result.
Facebook Twitter Google+ Linked in
Tuberculosis (TB) Test

Tuberculosis (TB) Test

Modelo: QIAreach QuantiFERON-TB
Solicite información

Descripción:

The QIAreach QuantiFERON-TB is a portable device that enables the ultrasensitive digital detection of TB infection with an end-to-end workflow that is simple and cost efficient, and increases access to reliable Interferon Gamma Release Assay (IGRA) testing.
Más info

Descripción completa Características:

Descripción

The QIAreach QuantiFERON-TB is a portable device that enables the ultrasensitive digital detection of TB infection with an end-to-end workflow that is simple and cost efficient, and increases access to reliable Interferon Gamma Release Assay (IGRA) testing. Built on the proven QuantiFERON-TB Gold Plus technology, it uses blood samples to test for interferon-gamma molecules released from T-cells that have come into contact with TB bacteria. QIAreach QuantiFERON-TB runs these tests on the digital eHub and eStick system, a true walkaway solution with random access and no calibration or maintenance. QIAreach QuantiFERON TB testing requires one patient visit and produces an easy-to-read result in 20 minutes after sample incubation, with the ability to record and send results for improved data management, making it ideal for TB screening programs. Solicite información

Características:

• Field-friendly, portable
• Robust and scalable
• No complex laboratory required
• Objective, digital results Solicite información

Enviar un mensaje al proveedor

* Información requerida
* Email:
Para
QIAGEN ()
* Mensaje

Derecho de autor © 2000-2021 TradeMed.com. Todos los derechos reservados. | Términos y condiciones